SCHEMBL827495

SCHEMBL827495

CCOC(=O)Cn1nc(Nc2ccc3c(c2)OC(F)(F)O3)nc1-c1ccnc(C)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.43
▸ TSHR P16473 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA2B P29275 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ BRAF P15056 9/20 0.36
▸ KIT P10721 8/20 0.36
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ SYK P43405 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL827727 0.92 CYP1A2 (0.42) CYP1A2TSHRADORA3ADORA2AADORA2B
SCHEMBL12450325 0.91 CYP1A2 (0.42) CYP1A2TSHRADORA3ADORA2AADORA2B
SCHEMBL827708 0.90 CYP1A2 (0.42) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL827578 0.88 CYP1A2 (0.41) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL2340465 0.87 CYP1A2 (0.39) CYP1A2TSHRADORA3ADORA2AADORA2B
SCHEMBL827982 0.84 CYP1A2 (0.39) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL827764 0.83 CYP1A2 (0.39) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL827698 0.80 CYP1A2 (0.41) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL2343141 0.79 ADORA3 (0.41) CYP1A2ADORA3ADORA2AADORA2BADORA1
SCHEMBL827668 0.76 CYP1A2 (0.38) CYP1A2ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 CYP1A2 438/4885TSHR 88/4885ADORA3 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback